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Tumor development depends on the inter-
action between cancer cells and surrounding 
nonmalignant stroma. Stroma is composed of 
nonhematopoietic cells (fi  broblasts and endo-
thelial cells) and immune cells from both the 
innate and the adaptive immune systems (1, 2). 
These two arms of the immune system are con-
nected by DCs (3–6). DCs induce and maintain 
immune response and, as opposed to macro-
phages, are able to prime naive lymphocytes. 
The outcome of this interaction depends on 
DC activation/maturation (3). Thus, presenta-
tion of antigen by immature (nonactivated) 
DCs leads to tolerance (7–9), whereas mature 
DCs are geared toward the launching of anti-
gen-specifi  c immunity (10). Furthermore, vac-
cination with antigen-loaded DCs in both mice 
and humans can lead to the break of tolerance 
to cancer (for review see 11). Therefore, DCs 
might represent an early target for subversion 
by developing tumors.
The immunological consequences of DC 
infi  ltration are not well understood, although 
many studies in humans reported infi  ltration of 
various tumor types with DCs (for review see 
12). Inhibition of DC maturation and function 
is thought to represent one of the means through 
which tumors evade the immune system (12). 
For example, increased production of vascular 
endothelial growth factor (13) inhibits DC mat-
uration (14), thereby resulting in the induction 
of tolerance. IL-6 secreted by breast cancer cells 
can switch monocyte diff  erentiation into macro-
phages at the expense of DCs (15), thereby 
skewing antigen presentation toward antigen 
degradation (16). Finally, certain tumors were 
shown to promote diff  erentiation of IL-10 and/
or TGF-β–secreting DCs that in turn expand 
CD4+CD25+ regulatory T cells (17–19). These 
are able to inhibit antitumor eff  ector cells, thereby 
contributing to tumor escape (20).
We found that human breast cancer tumors 
are infi  ltrated with DCs (21), including imma-
ture myeloid DCs in tumor beds and mature 
DC-LAMP+ DCs in peritumoral areas. Mature 
DCs are often found in clusters with CD4+ 
T cells, suggesting an ongoing immune res-
ponse (21). The presence of mature DCs outside 
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lymphoid organs is linked with inflammation and can be 
observed in the synovia of patients with rheumatoid arthritis 
(22, 23) (24) or in the blood of patients with systemic autoim-
mune disease (25, 26). However, the immunological consequen-
ces of the presence of mature DCs in tumors remain unknown.
In this paper, we have studied the CD4+ T cells infi  ltrat-
ing human breast cancer tumors. We found the presence of 
IL-13–secreting CD4+ T cells. We also found IL-13 stain-
ing on breast cancer cells. To understand the role of IL-13 
in vivo, we used our model of humanized mice (27), which 
we additionally grafted with breast cancer cell lines (un-
published data). These immunodefi  cient nonobese diabetic/
LtSz-scid/scid  β2 microglobulin–defi  cient  (NOD/SCID/
β2m−/−) mice transplanted with human CD34+ hematopoietic 
progenitor cells (HPCs) develop all subsets of human DCs 
and B cells (27). T cells are adoptively transferred. We found 
that breast cancer polarizes CD4+ T cells in vivo via DCs. 
These polarized CD4+ T cells secrete IL-13, which contributes 
to accelerated tumor development.
RESULTS
Breast cancer tumors are infi  ltrated with CD4+ T cells 
secreting IL-13
We measured T cell cytokines, both type 1 (IFN-γ) and type 2 
(IL-4 and IL-13), in supernatants of breast cancer tumor 
fragments activated for 16 h with PMA/ionomycin (n = 19; 
tumor characteristics are given in Table I). As shown in Table 
II, high levels of IL-2 (3.3 ± 0.8 ng/ml; 17 out of 19 samples) 
and IFN-γ (4.1 ± 1.5 ng/ml; 17 out of 19 samples), as well 
as IL-13 (209 ± 67 pg/ml; 15 out of 19 samples) and IL-4 
(33 ± 11 pg/ml; 9 out of 19 samples; mean ± SEM for all), 
were found. The levels were signifi  cantly higher in superna-
tants from tumor sites compared with supernatants from 
macroscopically uninvolved surrounding tissue (Table II).
Flow cytometry on single-cell suspensions demonstrated the 
presence of T cell infi  ltrate with a prevalence of CD3+CD4+ 
T cells over CD3+CD8+ T cells (11 ± 3% and 5 ± 1%, 
  respectively; n = 18; P = 0.01). Intracellular staining of single-
cell suspensions after 5 h of activation with PMA/ionomycin 
demonstrated expression of IFN-γ, as well as IL-13, by CD4+ 
T cells (Fig. 1, A and B). The IL-13 staining was specifi  c, as 
it could be blocked by excess recombinant IL-13 (Fig. 1 B). 
The mean frequency of IL-13–expressing CD4+ T cells in 
11 samples analyzed was 4 ± 0.6% (range 0.2–9%). Two types 
of CD4+ T cell staining were observed: double-positive cells 
expressing both IL-13 and IFN-γ (Fig. 1 B) in a majority of 
tumors and, in some tumors, single-positive cells expressing 
either IL-13 or IFN-γ (Fig. 1 A), the latter one consistent 
with the defi  nition of T cell polarization (28). CD4+ T cells 
expressing chemoattractant receptor–homologous molecule 
expressed on Th2 cells (CRTH2) (29, 30) were detected by 
fl  ow cytometry (14 ± 2%; n = 6; Fig. 1 C). In four out of 
six analyzed tumors, the infi   ltration with CRTH2+CD4+ 
T cells was signifi  cantly higher in the tumor sites compared with 
macroscopically uninvolved surrounding tissue (P = 0.03; Fig. 
1 D). Thus, breast cancer tumors from patients are infi  ltrated 
with CD4+ T cells secreting IFN-γ and IL-13. 
Breast cancer cells express IL-13 and phosphorylated 
STAT6 (pSTAT6)
To determine IL-13 expression in situ, breast cancer tissue 
sections were stained with specifi  c mAb and analyzed by 
Table I.  Tumor sample characteristics
Sample no. Histopathological diagnosis Grade Stage
7 Invasive duct carcinoma III IIA
8 In-situ and invasive duct carcinoma III na
9 Infi  ltrating carcinoma, mixed lobular, and ductal I IIB
11 Infi  ltrating ductal carcinoma, microinvasive Intermediate na
12 Invasive high grade ductal carcinoma nd IIB
13 Infi  ltrating ductal carcinoma II na
15 Infi  ltrating ductal carcinoma with lobular feature II I
16 Infi  ltrating carcinoma, predominantly ductal with lobular 
feature
II
17 Invasive duct carcinoma I na
18 Invasive duct carcinoma I and II na
19 In-situ and invasive ductal carcinoma II I
20 In-situ and invasive ductal carcinoma III IIA
21 Infi  ltrating lobular carcinoma, pleomorphic type nd na
22 Invasive ductal carcinoma II na
23 In-situ and invasive ductal carcinoma III IIB
24 In-situ and invasive ductal carcinoma III IIA
25 Multifocal ductal carcinoma in situ with comedo necrosis III I
26 In-situ and invasive duct carcinoma III IIA
27 Invasive and in-situ ductal carcinoma III na
Characteristics of analyzed breast cancer tumors from patients. Histopathology, tumor grade, and clinical stage are shown. nd, not determined; na, not available.JEM VOL. 204, May 14, 2007  1039
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Figure 1.  Breast cancer is infi  ltrated with CD4+ T cells secreting 
type 1 and type 2 cytokines. (A and B) Intracellular staining of IL-13 
and IFN-γ on gated CD3+CD4+ T cells infi  ltrating breast cancer. Flow 
cytometry plots (A) and (B) represent samples from two different patients. 
To demonstrate specifi  city, anti–IL-13 mAb was pretreated with rhIL-13 
before staining. (C) Representative fl  ow cytometry analysis of CRTH2 
expression by gated CD3+CD4+ T cells. In A–C, numbers indicate the per-
centage of cells positive for the specifi  ed marker. (D) Percentage of 
CRTH2+CD4+ T cells (ordinate) within breast cancer tumor or correspond-
ing macroscopically not involved surrounding tissue (n = 6 patients). 
P = 0.03 using the paired t test.
Table II.  T cell cytokines in supernatants of whole-tumor fragments or surrounding tissue
IL-2 (pg/ml) IFN-γ (pg/ml) IL-4 (pg/ml) IL-13 (pg/ml)
Sample no. ST Tumor ST Tumor ST Tumor ST Tumor
7 1,041 5,489 1,030 2,929 5 13 0 123
8 12 7,517 0 1,311 0 33 0 343
9 0 588 0 798 0 5 0 85
11 114 3,512 181 2,459 0 199 0 310
12 348 2,108 904 3,887 22 66 43 395
13 262 280 83 149 0 0 0 24
15 750 1,456 1,013 1,769 5 25 0 60
16 0 236 0 543 0 0 0 0
17 164 2,641 218 3,554 0 0 0 19
18 0 75 0 124 0 0 0 47
19 172 6,281 211 13,170 0 43 0 128
20 8,410 7,067 7,304 6,774 0 11 54 87
21 1,436 13,022 3,087 27,599 6 39 6 931
22 0 5 0 0 2 3 0 0
23 1,665 0 558 0 6 2 6 0
24 590 870 135 1,376 6 6 12 31
25 81 2,371 92 777 7 52 3 263
26 2,035 3,052 1,352 1,855 13 49 63 123
27 1,815 7,553 1,454 8,959 10 77 84 1,001
p-value 
(t test) 0.007 0.03 0.01 0.007
The breast cancer microenvironment is rich in type 2 cytokines. Size-comparable ( 10-mm3) fragments of breast cancer tumor or macroscopically uninvolved surrounding 
tissue (ST) were stimulated for 16 h with PMA/ionomycin, and the cytokines IL-2, IFN-γ, IL-4, and IL-13 were analyzed in the supernatant by multiplex cytokine analysis 
(pg/ml; n = 19 patients). Values for each analyzed patient are shown. p-values refl  ect a comparison of cytokine concentration in the supernatants of breast cancer tumor or 
macroscopically uninvolved surrounding tissue (using the paired t test).1040  DCS IN BREAST CANCER INDUCE CD4 T CELLS MAKING TYPE 2 CYTOKINES | Aspord et al.
immunofl  uorescence. As expected based on fl  ow cytometry 
analysis, T cells staining with IL-13 could be found (unpub-
lished data). However, a major IL-13 staining was found in 
large cells organized in nests, consistent with the staining on 
cancer cells (Fig. 2 A, left). To confi  rm this, the tissue was 
counterstained with cytokeratin (Fig. 2 A, middle). Indeed, 
nearly all cytokeratin-expressing cancer cells coexpressed 
IL-13 (Fig. 2 A, right). This staining was abolished by the excess 
Figure 3.  Breast cancer cells express pSTAT6. Immunohistochemistry 
on paraffin-embedded tissue sections (A–C) and (D and E) represent 
tumors from two different patients. (A–C) A nest of breast cancer cells 
expressing cytokeratin (A) can also be stained with antibody recognizing 
STAT6 (B), as well as with an antibody recognizing pSTAT6 (C). 
(D and E) pSTAT6 staining is predominantly found on cancer nests (D) 
and can be blocked by a peptide used to generate the antibody (E). 
Bars, 100 μm.
Figure 2.  IL-13 staining on breast cancer cells. (A) Frozen breast 
cancer tumor sections were labeled with cytokeratin (green) and IL-13 
(red). (B) Section from tumor obtained from a different patient. IL-13 
staining of breast cancer cells can be inhibited by rhIL-13. Bars: (A) 20 μm; 
(B) 50 μm.JEM VOL. 204, May 14, 2007  1041
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of recombinant human (rh) IL-13 (Fig. 2 B) demonstrating 
specifi  city. IL-13 staining could be detected in 11 out of 
11 breast cancer tumor samples analyzed (Fig. 2, A and B).
Phosphorylation of STAT6 is considered a signature of 
IL-13 (and/or IL-4) signaling (31–33). All analyzed breast 
cancer tumor samples showed expression of STAT6 by cancer 
cells (Fig. 3, A and B; and not depicted). 8 out of 11 tumors 
showed cytoplasmic expression of pSTAT6, and three of these 
tumors showed strong expression (Fig. 3, C and D). The stain-
ing was blocked by excess peptide that was used to generate 
anti-pSTAT6 antibody demonstrating specifi  city (Fig. 3 E).
Thus, in breast cancer tumors, T cells and breast cancer 
cells express IL-13. Breast cancer cells also express pSTAT6, 
suggesting that IL-13 actually delivers signals to cancer cells.
Figure 4.  CD4+ T cells promote development of breast cancer 
tumors. (A) Experimental scheme. (B and C) 100 μl PBS (36 mice analyzed) 
and 10 × 106 autologous CD8+ T cells/100 μl PBS (21 mice analyzed) 
alone or together with 10 × 106 CD4+ T cells/100 μl PBS (55 mice analyzed) 
were transferred into Hs578T breast tumor–bearing humanized mice 
three times at days 3, 6, and 9 after tumor implantation. Kinetics of tumor 
development (mean ± SD; B, curves) and tumor size at day 12 (each dot 
represents one mouse; C) are shown. Horizontal bars represent the mean. 
(D) Experimental scheme. (E) CD4+ T cells generated as in A were purifi  ed 
from tumors and transferred into Hs578T tumor-bearing humanized mice. 
Tumor size at day 11 is shown (two experiments with four recipients per 
Humouse). Horizontal bars represent the mean.
Figure 5.  CD4+ T cells promote development of breast cancer 
tumors through DCs. (A) Experimental scheme. (B) 100 μl PBS or 10 × 
106 CD4+ and CD8+ T cells/100 μl PBS were transferred into Hs578T 
tumor-bearing mice. The tumor size 12 d after tumor inoculation is 
shown for two experiments (nine mice per group). Horizontal bars 
represent the mean. (C) 100 μl PBS, and 106 DCs/100 μl PBS and 10 × 
106 autologous CD4+ T cells/100 μl PBS, or both, were transferred into 
Hs578T tumor-bearing mice. Tumor growth was monitored (three mice 
per group; mean ± SD).1042  DCS IN BREAST CANCER INDUCE CD4 T CELLS MAKING TYPE 2 CYTOKINES | Aspord et al.
CD4+ T cells promote the development of breast cancer 
tumors in vivo
Humanized mice were then used to demonstrate the link 
between breast cancer and IL-13–secreting CD4+ T cells. 
The experimental scheme is given in Fig. 4 A. There, sub-
lethally irradiated adult NOD/SCID/β2m−/− mice were 
transplanted with human G-CSF––mobilized CD34+HPCs 
from a healthy donor (27). 4 wk later, when these mice dis-
play human DCs and B cells, 107 Hs578T breast cancer cells 
were implanted subcutaneously into the fl  ank (unpublished 
data). Mice were then reconstituted with T cells autologous 
to the grafted CD34+HPCs (Fig. 4 A). Repeated injections 
of 10 × 106 T cells (both CD4+ and CD8+) resulted in ac-
celerated tumor development (Fig. 4 B). Indeed, at day 15, 
the tumor volume tripled (P < 0.0001; Fig. 4, B and C). This 
was dependent on CD4+ T cells, as reconstitution with puri-
fi  ed CD8+ T cells did not aff  ect early tumor development 
(Fig. 4, B and C).
To analyze whether CD4+ T cells actually confer the ac-
celeration of tumor development, CD4+ T cells were sorted 
from day 15 Hs578T breast cancer tumors pooled from sev-
eral donor humanized mice. These in vivo primed CD4+ T 
cells were then injected into humanized mice bearing Hs578T 
breast cancer tumors but no T cells (Fig. 4 D, experimental 
scheme). Control mice received PBS. A single transfer of 
1.5 × 106 in vivo primed CD4+ T cells per recipient mouse 
led to acceleration of breast cancer tumor development in 
three out of four tested mice in two independent experiments 
(mean tumor volume ± SEM = 51 ± 17 in control mice that 
received PBS vs. 167 ± 27 in experimental mice that received 
T cells; P = 0.06; Fig. 4 E).
To determine whether the human DCs had any role in   tumor 
development, we used NOD/SCID/β2m−/− mice without 
CD34+HPC grafts into which we implanted Hs578T breast 
cancer cells (Fig. 5 A, experimental scheme). As shown in 
Fig. 5 B, no change in tumor volume was observed upon in-
jection of T cells isolated from diff  erent donors. However, 
coinjection of autologous DCs (generated by culturing mono-
cytes with GM-CSF and IL-4) and CD4+ T cells led to 
  acceleration of breast cancer tumor development (Fig. 5 C). 
Thus, CD4+ T cells require DCs to promote the development 
of breast cancer tumors.
CD4+ T cells are polarized in vivo to secrete IL-13
To analyze cytokine secretion in vivo, CD4+ T cells were 
sorted from the tumors of humanized mice 15 d after transfer. 
IL-2 (>10 ng/ml; not depicted), IFN-γ (>10 ng/ml; not 
depicted), IL-13 (mean ± SEM = 1,080 ± 200 pg/ml; n = 4; 
Fig. 6 A), and IL-4 (406 ± 48 pg/ml; n = 4; Fig. 6 B) were 
detected in supernatants of PMA/ionomycin-activated CD4+ 
T cells. Up to 17% of CD4+ T cells showed IL-13 expres-
sion by fl  ow cytometry (13 ± 3% of IL-13+CD4+ T cells; 
Fig. 6 C). Most of the IL-13–expressing CD4+ T cells also 
expressed IFN-γ (Fig. 6 C), as observed in some of the patient 
tumors. Thus, breast cancer tumors in humanized mice are 
infi  ltrated with CD4+ T cells secreting IL-13, as in patient 
tumor samples.
Breast tumors instruct DCs to induce CD4+ T cells 
secreting IL-13
To determine whether DCs represent the link between breast 
cancer and IL-13–secreting CD4+ T cells, we sorted DCs 
from Hs587T breast cancer tumors and their draining lymph 
nodes established in humanized mice without adoptively 
transferred T cells and analyzed their function in vitro. The 
experimental scheme is given in Fig. 7 A. As described else-
where, breast cancer tumors implanted in humanized mice 
attract human DCs (unpublished data). DCs were sorted at 
day 4 after tumor implant based on the expression of lineage 
markers and HLA-DR (Fig. 7 B) and were assessed in vitro 
for their capacity to trigger allogeneic naive T cell prolifera-
tion and cytokine secretion. After 5 d, T cells were activated 
with PMA and ionomycin, and cytokines were assessed in the 
supernatants (Fig. 7 A). DCs isolated from both tumors and 
their draining lymph nodes induced allogeneic CD4+ T cells 
to proliferate and secrete large amounts (>10 ng/ml) of IL-2 
and IFN-γ (unpublished data). Furthermore, high levels of 
IL-4 and IL-13 were found (mean concentration ± SEM = 
205 ± 78.5 and 3,345 ± 1,508 pg/ml IL-4; and 1,775 ± 
745 and 7,961 ± 1,342 pg/ml IL-13 for tumor- and, particu-
larly, for draining lymph node–derived DCs, respectively; 
Fig. 7 C). Flow cytometry confi  rmed the presence of CD4+ 
T cells expressing IL-13 with or without IFN-γ (Fig. 7 D). 
The capacity of DCs to induce large amounts of IL-4 and 
IL-13 secretion from naive CD4+ T cells was specifi  c to breast 
Figure 6.  CD4+ T cells isolated from tumors secrete IFN-𝗄 as well 
as type 2 cytokines. 10 × 106 autologous CD4+ and CD8+ T cells /100 μl 
PBS were transferred into Hs578T breast tumor–bearing humanized mice 
at days 3, 6, and 9 after tumor inoculation. At day 15, T cells were purifi  ed 
from tumors and restimulated in vitro overnight with PMA/ionomycin. 
(A and B) Cytokine secretion was measured in the supernatant by Luminex 
(four humanized mice per group). Error bars represent the mean ± SEM. 
(C) Intracellular cytokine staining was also performed after restimulation in 
presence of Brefeldin A (B; two experiments with seven humanized mice). 
Numbers indicate the percentage of cells positive for the specifi  ed marker.JEM VOL. 204, May 14, 2007  1043
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cancer, as DCs isolated from the lymph nodes draining mela-
noma tumors established in the same cohort of mice triggered 
signifi  cantly less IL-13 and IL-4 secretion (mean concentra-
tion ± SEM = 269.5 ± 94 and 4,119 ± 1,760 pg/ml IL-4 
for melanoma and breast cancer, respectively [P = 0.03]; and 
1,848 ± 828.5 and 9,261 ± 430 pg/ml IL-13 for melanoma 
and breast cancer, respectively [P = 0.03]; Fig. 7 E). Further-
more, although at day 4 after breast tumor implant the capac-
ity of DCs to trigger IL-13 and IL-4 secretion was particularly 
apparent in draining lymph nodes (Fig. 7 C and not depicted), 
at day 30 it was clearly confi  ned to DCs isolated from breast 
cancer tumors and their draining lymph nodes (Fig. 7 F). Thus, 
breast cancer instructs DCs to prime a fraction of CD4+ T cells 
to produce IL-4 and IL-13.
IL-13 antagonists prevent breast cancer tumor development
To establish if IL-13 plays any role in the observed breast can-
cer tumor development, humanized mice bearing Hs587T 
breast cancer tumors were treated with an antibody-neutral-
izing IL-13 and a soluble IL-13R. As shown in Fig. 8 A, mice 
treated with both IL-13 antagonists showed sustained inhibi-
tion of tumor development. Tumor volume at day 13 was 
39 ± 5 mm3 in animals without T cells (PBS control) and 
128 ± 18 in animals with T cells (mean tumor volume ± 
SEM; P = 0.01; Fig. 8 B). Neutralizing anti–IL-13 mAb alone 
was suffi     cient to prevent acceleration in breast cancer 
  tumor development (mean tumor volume at day 11 = 172 ± 
13 in animals treated with isotype control and 70 ± 11.5 
in animals treated with IL-13–neutralizing mAb; P = 0.03; 
Figure 7.  Breast cancer instructs DCs to induce CD4+ T cells to 
secrete type 2 cytokines. (A) Experimental scheme. (B) Representative 
FACS analysis of breast cancer tumor cell suspension showing staining 
with HLA-DR (ordinate) and lineage (abscissa) mAbs. HLA-DR+Lin− DCs 
are sorted from tumors and draining lymph nodes and co-cultured for 5 d 
with allogeneic naive CD4+ T cells at a ratio 1:10. (C) Cytokine secretion 
to co-culture supernatants measured with multiplex bead analysis after 
overnight PMA/ionomycin restimulation. Each dot represents a separate 
Humouse tumor. Draining lymph nodes were pooled to obtain a suf-
fi  cient number of cells for analysis. Horizontal bars represent the mean. 
(D) Intracellular cytokine expression by CD4+ T cells primed with DCs 
sorted from day 4 tumors and restimulated for 5 h with PMA/ionomycin 
in the presence of Brefeldin A. Dot plots are gated on CD3+CD4+ T cells 
(representative of n = 8 Humouse). Numbers indicate the percentage of 
cells positive for the specifi  ed marker. (E) IL-13 and IL-4 response in breast 
cancer, but not melanoma, environment. HLA-DR+Lin− DCs were sorted 
from lymph nodes draining Hs578T breast or Me275 melanoma tumors 
(day 4; lymph nodes were pooled from a total of 15 Humouse per group 
in four independent experiments). Horizontal bars represent the mean. 
P = 0.03 using the paired t test. (F) HLA-DR+Lin− DCs were sorted from 
tumors, draining lymph nodes, spleen, and BM of Hs578T breast cancer–
bearing Humouse (day 30; n = 22 Humouse). Sorted DCs were co-
cultured for 5 d with allogeneic naive CD4+ T cells at a ratio 1:10. Cytokine 
secretion was measured with multiplex bead analysis after overnight 
PMA/ionomycin restimulation. Box and whiskers data representation 
show median, range, and SE.1044  DCS IN BREAST CANCER INDUCE CD4 T CELLS MAKING TYPE 2 CYTOKINES | Aspord et al.
Fig. 8 C). Thus, accelerated development of breast cancer 
tumors in the humanized mouse (Humouse) reconstituted 
with CD4+ T cells can be partially prevented by treatment 
with IL-13 antagonists.
D  I  S  C  U  S  S  I  O  N 
We identifi  ed CD4+ T cells secreting IFN-γ and IL-13 in 
breast cancer tumors. We also found that breast cancer cells 
express IL-13. The production of IL-13 by CD4+ T cells 
infi  ltrating breast cancer suggests the paracrine origin of the 
IL-13 staining. It is, however, also possible that breast cancer 
cells might be induced to secrete IL-13, though we did not 
fi  nd expression in breast cancer cell lines in vitro or in vivo in 
the absence of T cells (unpublished data). Autocrine IL-13 
has been shown important in the pathophysiology of Hodgkin’s 
disease (32, 34, 35). There, IL-13 and IL-13R are frequently 
expressed by Hodgkin and Reed-Sternberg cells (35), and 
IL-13 stimulates their growth (34, 36). Similar to Hodgkin’s 
cells (32), breast cancer cells express pSTAT6, suggesting that 
IL-13 actually delivers signals to cancer cells. Accordingly, 
earlier in vitro studies demonstrated that IL-13 (as well as IL-4) 
can inhibit estrogen-induced proliferation and favor acqui-
sition of a breast cancer cell diff  erentiation marker, gross cys-
tic disease fl  uid protein–15 (37, 38). In line with the possible 
direct eff  ect of IL-13 on breast cancer cells in vivo are recent 
fi  ndings on the expression of IL-13Rα2 in highly aggressive 
variants of breast cancer with the propensity to form lung 
metastasis (39).
Humanized mice bearing breast cancer tumors permitted 
us to conclude that CD4+ T cells and IL-13 are actually in-
volved in breast cancer pathophysiology. There, CD4+ T 
cells promote early tumor development, which can be par-
tially prevented by IL-13 antagonists. The mechanism of this 
tumor development needs to be determined. In addition to a 
possible direct eff  ect on breast cancer cells, indirect mecha-
nisms need also be considered. There is clearly enhanced 
angiogenesis (unpublished data), which might be caused by 
activation of type 2 macrophages (40, 41). Furthermore, DCs 
Figure 8.  CD4+ T cells promote tumor development via IL-13. 
100 μl PBS or 10 × 106 autologous T cells/100 μl PBS were transferred 
into Hs578T breast tumor–bearing humanized mice at days 3 and 6 after 
tumor inoculation. Isotype or a mixture of anti–IL-13 antibody and rhIL-
13Rα2/Fc chimera (100 μg per injection) were administrated at days 4, 6, 
and 8 after tumor implantation. (A) Kinetic of tumor size. Error bars repre-
sent the mean ± SEM. (B and C) Tumor size 13 d after tumor inoculation 
is shown (two experiments with six humanized mice per group). Data in 
C are from one of the experimental cohorts shown in B. Horizontal bars 
represent the mean.JEM VOL. 204, May 14, 2007  1045
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in such a microenvironment could acquire a suppressive pheno-
type involving, for example, indoleamine 2,3-dioxygenase 
expression (42) or, as discussed earlier, TGF-β production 
(17–19, 43). The role of IL-13 in the indirect suppression 
of tumor surveillance has been demonstrated in other tumor 
models (43–46) and is frequently linked with suppression 
of cytotoxic T cell function. There, blockade of IL-13 per-
mitted inhibition of tumor growth and eventual rejection. 
Our preliminary results suggest that at least CD8+ T cell 
priming is not inhibited in our model in the presence of 
CD4+ T cells. Further studies are needed to establish whether 
their in vivo function and capacity to reject breast cancer 
tumors is altered.
Our study further demonstrates that CD4+ T cells facili-
tate tumor development, provided DCs are present. This 
ménage a trois generates an environment rich in IL-13 pro-
duced by T cells. Indeed, DCs infi  ltrating breast cancer tu-
mors in humanized mice appear responsible for the induction 
of IL-13–secreting CD4+ T cells, at least in the initial phase 
of tumor development. Two patterns of cytokine expression 
by CD4+ T cells were observed. The fi  rst, with the presence 
of single-positive CD4+ T cells expressing either IL-13 or 
IFN-γ, is consistent with the classical defi  nition of type 2 
polarization (28). This suggests bona fi  de Th1 and Th2 cells 
in the breast cancer tumor microenvironment. The second 
pattern, found in the majority of tumors from patients, is the 
presence of double-positive IL-13– and IFN-γ–expressing 
CD4+ T cells, possibly refl  ecting Th0 cells (28). The pres-
ence of double-positive cells could also refl  ect some degree 
of plasticity in Th1/Th2 cell polarization, particularly in the 
presence of high IFN-γ (33). Such plasticity has been dem-
onstrated by genetic reprogramming of human Th1 and Th2 
cell clones (47, 48). IL-13 secretion by CD4+ T cells appears 
independent of the presence of invariant chain–expressing 
NKT cells, as their depletion does not aff  ect the frequency 
of IL-13–expressing CD4+ T cells in the in vitro experi-
ments (unpublished data). Finally, they appear restricted at 
large by MHC class II, as blocking HLA-DR on DCs leads 
to >90% inhibition of IL-13– secreting CD4+ T cells (un-
published data).
In conclusion, by combining the studies of human cancer 
using ex vivo analysis of patient samples and in vivo analysis 
in the model of the human immune system and human can-
cer, we demonstrated the immune deviation via DCs that 
breast cancer might use to develop. This immune deviation 
can be counteracted with IL-13 antagonists, pointing to the 
role of IL-13 in the pathophysiology of breast cancer.
MATERIALS AND METHODS
Generation of humanized mice. CD34+HPCs were obtained from 
apheresis of adult healthy volunteers mobilized with G-CSF and purifi  ed 
as previously described (27). The CD34− fraction of apheresis was Ficoll-
purifi  ed, and obtained PBMCs were stored frozen and used as a source of 
autologous T cells. 2.5 × 106 CD34+HPCs were transplanted intravenously 
into sublethally irradiated (12 cGy/g body weight of 137Cs γ irradiation) 
NOD/SCID/β2m−/− mice (Jackson ImmunoResearch Laboratories; Insti-
tutional Animal Care and Use Committee no. A01-005). 10 × 106 breast 
cancer cells (Hs578T) or 10 × 106 melanoma cells (Me275) were harvested 
from long-term cultures and injected subcutaneously into the fl  anks of the 
mice. For experiments with NOD/SCID/β2m−/− mice, they were suble-
thally irradiated the day before tumor implantation. Tumor size was moni-
tored every 2–3 d. Tumor volume (ellipsoid) was calculated as follows: 
(short diameter)2 × long diameter/2.
Monocyte-derived DCs and T cell purifi  cation. Monocyte-derived 
DCs were generated from the adherent fraction of PBMCs by culturing 
with 100 ng/ml GM-CSF (Immunex) and 25 ng/ml IL-4 (R&D Systems). 
CD4+ and CD8+ T cells were positively selected from thawed PBMCs 
using magnetic selection according to the manufacturer’s instructions   
(Miltenyi Biotec). The purity was routinely >90%.
Immunofl  uorescence. Tissues were frozen in optimal cutting temperature 
compound (Tissue-Tek; Allegiance), cryosectioned on slides (Superfrost Plus; 
Fisher Scientifi  c), and fi  xed with cold acetone. Direct staining was done 
with HLA-DR FITC (BD Biosciences), CRTH2-PE (Miltenyi Biotec), 
IL-13–PE (BD Biosciences), and CD3-FITC. Confocal microscopy was 
performed using a TCS-NT SP (Leica).
Flow cytometry. Cell suspensions were obtained from tumors by diges-
tion with 2 mg/ml collagenase D (Roche Diagnostics) for 45 min at 37°C. 
Bone marrow cells were washed out of the harvested bones. Cell suspen-
sions were washed twice and stained in PBS with serum (2 mM EDTA, 5% 
AB) using the following antibodies: Lin, CD45, HLA-ABC, and CD3-PE 
(all from BD Biosciences).
T cell cytokines. To assess cytokine expression by intracellular staining, 
T cells were restimulated for 5 h with PMA and ionomycin. 10 mg/ml 
Brefeldin A (BD Biosciences) was added for the last 2.5 h. T cells were la-
beled with anti-CD3 and antibodies to IL-4, IL-13, TNF, IFN-γ, and IL-2 
(BD Biosciences).
In vivo IL-13 blocking. Mice were injected intratumorally at days 4, 6, 
and 8 after tumor implantation with anti–IL-13 mAbs and rhIL-13Rα2/Fc 
chimera or goat IgG isotype control (100 μg/ml each; R&D Systems).
Tumor samples. Tumor samples from patients diagnosed with breast car-
cinoma (in situ and invasive duct and/or mucinous carcinoma of the breast, 
as well as lobular carcinoma) were obtained from the Baylor University 
Medical Center Tissue Bank (Institutional Review Board no. 005-145). 
Whole-tissue fragments were placed in culture with 50 ng/ml PMA and 
1 μg/ml ionomycin (Sigma-Aldrich) for 16 h. Cytokine production was an-
alyzed in the culture supernatant by Luminex (Beadlyte custom kit; Upstate 
Biotechnology). For cell suspensions, samples were minced into small frag-
ments and digested in a triple enzyme mix containing 2.5 mg/ml collage-
nase, 1 mg/ml hyaluronidase, and 20 U/ml DNase for 2–3 h at 37°C. The 
suspension was fi  ltered and washed, and obtained cells were resuspended at a 
concentration of 106 cells/ml and activated for 5 h with PMA and ionomycin. 
10 mg/ml Brefeldin A was added for the last 2.5 h. Cells were labeled with 
anti-CD3 and anti-CD4 mAb, and intracellular cytokine staining was per-
formed using antibodies to IL-13 and IFN-γ (BD Biosciences). For inhibi-
tion of IL-13 staining, anti–IL-13 mAb was incubated with 5 μg/ml rhIL-13 
for 1 h at room temperature before use. Cells were fi  xed in 1% PFA and ana-
lyzed by fl  ow cytometry. A piece of each tissue was frozen for immuno-
fl  uorescence analysis. Sections were labeled with CD3 Alexa Fluor 488 mAb 
(BD Biosciences) and mounted with DAPI.
STAT 6 detection in paraffi   n-embedded breast cancer tissue. The 
slides were deparaffi   nized in two changes of xylene, washed in 100% ethanol, 
and hydrated in 95% ethanol, 75% ethanol, and PBS. For antigen retrieval, the 
slides were placed in preheated to boiling temperature 10 mM sodium citrate, 
0.05% Tween, pH 6, in a pressure cooker and incubated for 8 min. Rinsed 
slides were incubated in 0.3% hydrogen peroxide for 8 min, rinsed in 1× 
PBS followed by a Biotin-Blocking kit (Invitrogen), and blocked with 1% 1046  DCS IN BREAST CANCER INDUCE CD4 T CELLS MAKING TYPE 2 CYTOKINES | Aspord et al.
BSA/0.1% saponin. They were then incubated overnight with the primary 
antibody (cytokeratin [DakoCytomation], STAT6 [BD Biosciences], or 
pSTAT6 [Cell Signaling]) overnight at room temperature at 0.8 μg/ml. The 
secondary antibody was goat anti–rabbit biotin from Invitrogen, used at a 
1:1,000 dilution for 30 min. Ready-to-use horseradish peroxidase–streptavidin 
was placed on the slides for 30 min (Vector Laboratories), followed by DAB 
substrate from BD Biosciences for 20 min, and counterstained with hema-
toxylin and mounted with Cytoseal XYL (Richard-Allan Scientifi  c). The 
images were acquired using a digital camera (DXM 1200C; Nikon).
DC–T cell co-cultures. Naive CD4+ T cells were obtained from buff  y 
coats after magnetic depletion using CD8, CD14, CD19, CD16, CD56, and 
glycophorine A microbeads (Miltenyi Biotec) and sorted based on the 
CD4+CCR7+CD45RA+ phenotype. NKT cells were depleted by exclu-
sion of Vα24+ CD4+ T cells from the sort gate. DCs were sorted based on 
HLA-DR+Lin−CD11c+ and HLA-DR+Lin-CD123+ phenotypes. 5 × 104 
naive CD4+ T cells/well were cultured with 5 × 103 DCs/well in RPMI 
1640 supplemented with 10% human AB serum (Gemini BioProducts). To 
assess cytokine secretion by Luminex, T cells were harvested at day 5, 
washed twice, resuspended at a concentration of 106 cells/ml, and restimu-
lated for 16 h with 50 ng/ml PMA and 1 μg/ml ionomycin (Sigma-
Aldrich). To assess cytokine expression by intracellular staining, T cells were 
harvested on day 6 of the culture, washed twice, and restimulated for 5 h 
with PMA and ionomycin. 10 mg/ml Brefeldin A was added for the last 2.5 h. 
T cells were labeled with anti-CD3 and antibodies to IL-4, IL-13, and 
IFN-γ (BD Biosciences).
Statistics. The parametric t test and nonparametric Mann-Whitney and 
Wilcoxon tests were used to assess the signifi  cance of observed diff  erences. 
The parametric Pearson correlation and nonparametric Spearman correla-
tion were used as indicated in the fi  gure legends.
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